GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...

The CDC’s vaccine advisors on Thursday maintained that respiratory syncytial virus immunization is only recommended for ...

Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the ...

Anyone who got sick with COVID-19 during the summer wave in South Florida has some protection against a future infection, but ...

Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...

Anyone who got sick with COVID-19 during the summer wave in South Florida has some protection against a future infection, but ...

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

2024 Future of Healthcategory US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease October 22, 2024 ...

Respiratory syncytial virus, or RSV, typically presents as mild, with symptoms similar to the common cold for adults and ...

Last week, GlaxoSmithKline and Northwestern University filed separate lawsuits against Moderna, accusing its mRNA-based vaccines of ...

On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

Avalon GloboCare signs MOU with Qi Diagnostics to co-develop a nanosensor-based cannabis breathalyzer. Talks aim for a ...